Univmed s.r.o.

Verified siteinfo

Czechia Zerotinovo Namesti 533/6, 602 00 Brno, Czechia

3 trials recruiting
Arteriosclerosis · Cardiac failure · Cardiovascular disorder
Adult patients

About Specializations

Univmed s.r.o. in Brno, Czechia specialises in clinical trials of conditions such as Arteriosclerosis, Cardiac failure, Cardiovascular disorder, Hypertension, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Research

The medical center is at the forefront of cardiovascular research, focusing on innovative treatments and interventions for cardiovascular disease. The center's research is pivotal in understanding and mitigating the risks associated with major cardiovascular events.

Innovative Lipoprotein (a) Lowering Therapies
Prevention of Major Adverse Cardiovascular Events (MACE)
Advanced Cardiovascular Risk Assessment

Through its cutting-edge research, the center contributes significantly to the development of therapies that aim to reduce the incidence of cardiovascular events, thereby improving patient outcomes and quality of life.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Zerotinovo Namesti 533/6602 00 BrnoCzechia

Open in maps ↗

Recruiting now: 3 trials
Conditions studied: 6
Partner status: Verified site

More sites in Brno Czechia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

5 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Czechia

Participants:18–64 years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S